For security, Pfizer watches suppliers

"Do not enter into supply agreements with companies that do not meet acceptable standards, and terminate agreements with companies that do not maintain acceptable standards." So says Gerry Migliaccio, senior VP for global manufacturing at Pfizer, in a Pharmaceutical Technology interview.

He says that's an oversimplification of one of the key elements of enforcement in a strategy for supply-chain security. Many factors are involved in evaluating suppliers, notes Migliaccio. But once basic viability has been established, he looks at their quality systems and environmental-management systems.

Migliaccio also notes in the interview that control of the suppliers to Pfizer's suppliers is among then most critical of supply chain security issues.

- see the article


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.